It's Trump's economy now. The latest financial numbers offer some warning signs.
Get Starting Point
A guide through the most important stories of the morning, delivered Monday through Friday.
Enter Email
Sign Up
When Friday's jobs report turned out to be decidedly bleak, Trump ignored the warnings in the data and fired the head of the agency that produces the monthly jobs figures.
Advertisement
'Important numbers like this must be fair and accurate, they can't be manipulated for political purposes,' Trump said on Truth Social, without offering evidence for his claim. 'The Economy is BOOMING.'
It's possible that the disappointing numbers are growing pains from the rapid transformation caused by Trump and that stronger growth will return — or they may be a preview of even more disruption to come.
Trump's aggressive use of tariffs, executive actions, spending cuts and tax code changes carries significant political risk if he is unable to deliver middle-class prosperity. The effects of his new tariffs are still several months away from rippling through the economy, right as many Trump allies in Congress will be campaigning in the midterm elections.
Advertisement
'Considering how early we are in his term, Trump's had an unusually big impact on the economy already,' said Alex Conant, a Republican strategist at Firehouse Strategies. 'The full inflationary impact of the tariffs won't be felt until 2026. Unfortunately for Republicans, that's also an election year.'
The White House portrayed the blitz of trade frameworks leading up to Thursday's tariff announcement as proof of his negotiating prowess. The European Union, Japan, South Korea, the Philippines, Indonesia and other nations that the White House declined to name agreed that the U.S. could increase its tariffs on their goods without doing the same to American products. Trump simply set rates on other countries that lacked settlements.
The costs of those tariffs — taxes paid on imports to the U.S. — will be most felt by many Americans in the form of higher prices, but to what extent remains uncertain.
'For the White House and their allies, a key part of managing the expectations and politics of the Trump economy is maintaining vigilance when it comes to public perceptions,' said Kevin Madden, a Republican strategist.
Just 38% of adults approve of Trump's handling of the economy, according to a July poll by The Associated Press-NORC Center for Public Affairs. That's down from the end of Trump's first term when half of adults approved of his economic leadership.
The White House paints a rosier image, seeing the economy emerging from a period of uncertainty after Trump's restructuring and repeating the economic gains seen in his first term before the pandemic struck.
Advertisement
'President Trump is implementing the very same policy mix of deregulation, fairer trade, and pro-growth tax cuts at an even bigger scale – as these policies take effect, the best is yet to come,' White House spokesman Kush Desai said.
The economic numbers over the past week show the difficulties that Trump might face if the numbers continue on their current path:
Friday's jobs report showed that U.S. employers have shed 37,000 manufacturing jobs since Trump's tariff launch in April, undermining prior White House claims of a factory revival.
Net hiring has plummeted over the past three months with job gains of just 73,000 in July, 14,000 in June and 19,000 in May — a combined 258,000 jobs lower than previously indicated. On average last year, the economy added 168,000 jobs a month.
A Thursday inflation report showed that prices have risen 2.6% over the year that ended in June, an increase in the personal consumption expenditures price index from 2.2% in April. Prices of heavily imported items, such as appliances, furniture, and toys and games, jumped from May to June.
On Wednesday, a report on gross domestic product — the broadest measure of the U.S. economy — showed that it grew at an annual rate of less than 1.3% during the first half of the year, down sharply from 2.8% growth last year.
'The economy's just kind of slogging forward,' said Guy Berger, senior fellow at the Burning Glass Institute, which studies employment trends. 'Yes, the unemployment rate's not going up, but we're adding very few jobs. The economy's been growing very slowly. It just looks like a 'meh' economy is continuing.'
Trump has sought to pin the blame for any economic troubles on Federal Reserve Chair Jerome Powell, saying the Fed should cut its benchmark interest rates even though doing so could generate more inflation.
Trump has publicly backed two Fed governors, Christoper Waller and Michelle Bowman, for voting for rate cuts at Wednesday's meeting. But their logic is not what the president wants to hear: They were worried, in part, about a slowing job market.
But this is a major economic gamble being undertaken by Trump and those pushing for lower rates under the belief that mortgages will also become more affordable as a result and boost homebuying activity.
His tariff policy has changed repeatedly over the last six months, with the latest import tax numbers serving as a substitute for what the president announced in April, which provoked a stock market sell-off. It might not be a simple one-time adjustment as some Fed board members and Trump administration officials argue.
Advertisement
Of course, Trump can't say no one warned him about the possible consequences of his economic policies.
Biden, then the outgoing president, did just that in a speech last December at the Brookings Institution, saying the cost of the tariffs would eventually hit American workers and businesses.
'He seems determined to impose steep, universal tariffs on all imported goods brought into this country on the mistaken belief that foreign countries will bear the cost of those tariffs rather than the American consumer,' Biden said. 'I believe this approach is a major mistake.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
AMD posts mixed Q2 results but offers better than expected Q3 outlook on AI sales
AMD (AMD) reported its second quarter results after the bell on Tuesday, missing on adjusted earnings per share (EPS), but beating analysts expectations on revenue. The company also provided better than anticipated Q3 guidance of between $8.4 billion and $9 billion. Wall Street was expecting $8.3 billion. The announcement comes ahead of rival and market leader Nvidia's (NVDA) own earnings report later this month. AMD stock was flat following the news. The company's shares are up 44% year to date and 29% over the last 12 months, while Nvidia shares are up 32% and 77%, respectively. For the quarter, AMD saw adj. EPS of $0.48 on revenue of $7.6 billion. Wall Street was expecting EPS of $0.49 on revenue of $7.4 billion, according to Bloomberg consensus estimates. AMD says it saw an $800 million impact from the Trump administration's ban on the sale of the company's MI308 AI chips to China. Nvidia took a $4.5 billion write-down from the ban in Q1 and said it expects a larger $8 billion hit in its second fiscal quarter. Trump reversed course on the ban last month, which should help make up for some of those losses in the coming quarters. AMD should also benefit from the launch of its MI350 line of AI chips, designed to go toe-to-toe with Nvidia's Blackwell-powered chips. According to AMD, the MI350 line, which includes the MI350X and MI355X, offers four times the AI compute performance and a 35x increase in inferencing capabilities versus its predecessors. AMD's Data Center segment revenue topped out at $3.2 billion, meeting Wall street expectations. The company saw $2.8 billion in the segment last year. Beyond the Data Center segment, AMD's Client business, which includes sales of CPUs for desktops and laptops, generated $3.6 billion in revenue versus an anticipated $2.5 billion. Email Daniel Howley at dhowley@ Follow him on X/Twitter at @DanielHowley. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Pfizer CEO shares 3 pillars of company's cost-cutting efforts
Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO Albert Bourla joins Market Domination to discuss the company's earnings results and cost-cutting efforts. He also notes that a manufacturing shift would require a grace period due to long timelines. To watch more expert insights and analysis on the latest market action, check out more Market Domination. Pfizer reporting a beat on revenue and earnings for its second quarter. But the pharmaceutical manufacturer is facing new hurdles with tariff threats and calls from President Trump to lower prices. Our own, Julie Hyman, and senior health reporter, Anjalee Khemlani, spoke with the CEO about cost-cutting efforts and the future of the firm. I would call it more its productivity enhancement and margin expansion. We do that by implementing three things. One, it is focus. So we stop doing things that they are not that important, and we double down on things that they are. The second is technology. Technology right now offers tremendous opportunities for improvement of productivity, particularly AI and simplification of our business process. There is a lot of waste that is happening when you have complicated structures that require usually more people than if you have streamlined your areas. And this is where we are. We have announced a program that we are on track to exceed actually this year. And then announced an additional 1.7 billions of cost reductions, 1.2 billions of that until '27 will happen in SGNA in administrative and marketing and selling expenses. And that will fall to the bottom line. 500 millions will happen in R&D, and that will be reinvested all back in R&D. So it's not just the cost-cutting though, obviously, investors also want to see growth on the top line, growth in revenues. You guys did have growth in revenues this quarter by 10%. And the revenue growth has been more volatile. So how do you keep that momentum going and also find stability? Yes. If you see the elements of our revenues, the volatile piece is mainly our COVID. Because COVID could happen in different quarters every year. Usually there are two waves every year and in sometimes like 23, one way, the summer or the winter are stronger. And the same as in 24. So it's a different year by year. So I think that's the variability. The rest of the business, it's a very strong, continuous growth momentum, I think, and new products and recently acquired products contributed 4.7 billion dollars in this first half of the year. And they are growing at 15%. So it's very solid. I do want to talk about the backdrop from Washington. Because that's something that involves, that affects not just you, but the whole industry. You're also currently the head of the Pharmaceutical Industry Association. You did say on the call that you have a special relationship with members of this administration. Of course, we've heard the president be critical of the industry. What do you feel you have been able to educate President Trump about to sort of better help him understand the industry's perspective? I said we have a special relation with the president because that relation was cemented during the COVID crisis. He was very concerned. He want to make sure that we speed up the development of vaccines. So we speak every second week. So he was very active and he would ask about studies and where we are, and what can we do to accelerate. So it was very, it was a bonding, let's say, exercise. No, I, I think he's educated. Of course, it doesn't go into the details, is not his job, but he understands the dynamics. I had multiple times the opportunity to discuss with him the impact that the middleman has in the prices in the US. And he understands this very well and he speaks very vocally about it. Other things that they are subsidizing, that they are taking out of the prices of pharma, so that the patient pays a lot, but then we don't collect all of that because it goes to other areas like 340B. So he, what he wants to achieve, it is to have a better deal. He's very competitive. He doesn't like that others paying less. And he wants to fix it and we are very productively discuss, productively discussing right now what we can do on that. And the president did say in an interview today that tariffs could eventually reach 250%. He's talking about a phase in of that. Are you confident that you'll avoid that outcome for the industry, that 250% on imports of pharmaceuticals? I don't want to speak for the president, but what he said today, which was very important also was that it will be a very small tariff in the first couple of years. And then he opened actually the window for a grace period. Because I had this discussion with him and I had this discussion with multiple other members of the administration, but a manufacturing site to be completed, it takes more than five years for our industry. We in North Carolina, we just completed, not just, but we completed recently a few years back, the build of one manufacturing site. But was one product only, and it took us four and a half years and that was our record. So you can't just say you need to do it immediately and pay tariffs until you transfer. We can't afford to pay tariffs and the investments to transfer. Right. Makes sense. I want to bring in our Anjalee Khemlani, who, of course, you also know, our senior health reporter to talk more about some of these issues. So Anj, I know you're also, of course, watching the pricing debate very closely. Yeah, that most favored nations clause. Albert, I love the letter. Got your special, you know, name crossed out on there from Trump. But going to the contents of it, I know you've already talked about the DTC push and getting that direct to consumer push. You've already unfolded a strategy there, so you're really ahead of the curve there. But I want to actually talk about the pricing part of it because we've had notes from analysts talking about how it's really unfeasible to do most favored nations pricing the way that it's laid out in that letter. Can you talk to us about how you're planning for that? We are planning for all different scenarios of different ways of implementing something like that. And we are discussing and making mitigation plans. But we don't know how that will end up. We are still discussing it with with the president, how and what will be the devil could be on the details in this case. And talking about the tariffs as well. I know that with the manufacturing push, the industry had been trying to really pull the president away from these tariffs and conversations around it with the more than $200 billion in investments. Explain to us how that works considering that 90% of prescription drugs are generics and those are the ones that are cheaper to make, come from overseas, have smaller margins. Therefore, not really appealing to companies like you to produce. Meanwhile, the branded drugs are mostly produced here with the API is coming from overseas. So can you just put it together for us on how it would really impact you with tariffs coming in? What components? Depends on the product and depends how the custom authorities define a country of origin. First of all, you are right that generics are more than nine prescriptions per 10 in the US. And those are the cheapest medicines anywhere in the world. The generic prices in the US are the cheapest of any medicine. I think again, patients are paying way more than the real price of the generics, because of ways that the insurance system and the benefits work. But even with that, they are the cheapest generics in the world. Then the 10% or less that they are, they're branded. Many of them are manufactured here, as you know, probably. We have 13 sites in the US of manufacturing. 11 are manufacturing plants and then two are gigantic warehouses, almost like a plant. So we do a lot of them here, but we over the years, we produce some stuff outside. And Ireland is a typical example, Switzerland is a typical example, other places are typical examples. And those we need to understand if they will be the API will dictate the country of origin or where the final product is made.
Yahoo
2 minutes ago
- Yahoo
More people disapprove of Trump than less in latest polls for California, US
Recent efforts by the Trump administration are shaping the future of California, from the effects of the 'Big, Beautiful Bill' on residents to how federal immigration enforcement policies could impact the state's economy. In July, California saw federal officials visit Alcatraz as part of President Donald Trump's interest in reopening the prison. More recently, efforts to redistrict Texas in favor of Republicans — championed by the president, as USA TODAY reported — have Gov. Gavin Newsom looking to countermaneuver it through California's maps. At the state level, Attorney General Rob Bonta said he's filed 37 lawsuits against the Trump administration, some of which pertain to education, public health, and FEMA-related funding. At the local level, numerous Californians attended one of dozens of local demonstrations held in mid-July to protest the Trump administration. Of course, not all Californians and state officials perceive Trump and his administration negatively. But based on two recent polls, the president's favorability can certainly improve in the blue states. In California, the president holds a net approval rating of -31.6 percentage points, according to The Economist. A Civiqs poll found that in California, 29% approve of Trump, 68% disapprove, and 3% neither approve nor disapprove as of Monday, Aug. 4. Back in late May, a Public Policy Institute of California survey found that 70% of Californians disapproved of Trump's handling of his job, just a single percentage point increase from a February survey. Here are several other recent polls to get a wider view of how people view the president's job performance. Trump approval rating: Gallup, New York Times and more The Economist/YouGov poll: 40% approve of Trump, 55% disapprove of Trump and 4% are not sure, according to figures retrieved on Tuesday, Aug. 5. Emerson College poll: A poll of U.S. voters conducted from July 21-22 found Trump's approval rating was at 46% while 47% disapproved. The credibility interval, similar to a margin of error, was plus or minus 2.5 percentage points. Fox News poll: A poll conducted from July 18-21 under the direction of Beacon Research and Shaw & Company research found that 46% approval of Trump's job performance while 54% disapprove. Gallup poll: Trump has a 37% approval rating in a poll from July 7-21, down several percentage points from his second term average of 42% so far. It's his lowest job approval rating to date in his second term. New York Times poll: New York Times tracks the 'daily average of polls conducted by dozens of different organizations,' showing that as of Tuesday, Aug. 5, the president's approval rating is at 44% while his disapproval rating is at 53%. Quinnipiac University poll: A poll from July 10-14 of self-identified registered voters nationwide found that 40% approved of Trump's handling of his job while 54% disapproved. The margin of effort was plus or minus 2.7 percentage points. Reuters/Ipsos poll: A poll from July 25-27 that surveyed 1,023 U.S. adults nationwide found 40% approved of Trump's performance while 56% disapproved. The poll had a margin of error of 3 percentage points. Paris Barraza is a trending reporter covering California news at The Desert Sun. Reach her at pbarraza@ This article originally appeared on Palm Springs Desert Sun: Trump approval rating: What polls show for California, the U.S.
